Yüksel Ürün Highlights Ten-year Survival Rates of CHAARTED Trial
Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X about an article A. Tripathi and colleagues authored:
“CHAARTED Ten-year survival rates: Time to re-think de-escalation! Achieving a PSA nadir below 0.2 ng/mL within 6 months is a strong predictor of overall survival, supporting its role in response-adapted de-escalation strategies.”
Yao Zhu, Associate Professor in Oncology at Shanghai Medical College, added a comment to this post:
“De-escalation is a critical need. However, cycling APRI may increase CR in metastases. Further exploration of consolidative therapy in PSA-nadir patients is warranted. Data from SOLAR, SATURN, and ORIOLE trials:”
Title: Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial
Authors: A. Tripathi, Y. Chen, D.F. Jarrard, J.A. Garcia, R. Dreicer, G. Liu, M.H. Hussain, D.H. Shevrin, M.M. Cooney, M.A. Eisenberger, M. Kohli, E.R. Plimack, N.J. Vogelzang, J. Picus, M.A. Carducci, R.S. DiPaola, C.J. Sweeney
More posts featuring Yüksel Ürün.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023